MannKind | MNKD - Current Liabilities


MannKind reported $109.13M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Adma Biologics USD 56.49M 18.45M Sep/2025
BioCryst Pharmaceuticals USD 190.24M 13.08M Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Karyopharm Therapeutics USD 87.16M 12.06M Sep/2025
MacroGenics USD 44.47M 5.47M Sep/2025
MannKind USD 109.13M 2.7M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Minerva Neurosciences USD 2.67M 143K Sep/2025
Novavax USD 429.87M 40.73M Sep/2025
Novo Nordisk DKK 32.79B 203.33B Jun/2025
Pfizer USD 36.6B 1.13B Sep/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Xencor USD 86.48M 9.6M Sep/2025